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Abstract: Transcatheter aortic valve implantation (TAVI) has emerged as an important alternative to
surgical aortic valve repair (SAVR) for patients with severe aortic stenosis. This rapidly advancing
field has produced new-generation devices being delivered with small delivery sheaths, embolic
protection devices and improved retrieval features. Despite efforts to reduce the rate of thrombotic
complications associated with TAVI, valve thrombosis and cerebral ischaemic events post-TAVI
continue to be a significant issue. However, the antithrombotic treatments utilised to prevent these
dreaded complications are based on weak evidence and are associated with high rates of bleeding,
which in itself is associated with adverse clinical outcomes. Recently, experimental data has shed
light on the unique mechanisms, particularly the complex haemodynamic changes at sites of TAVI,
that underpin the development of post-TAVI thrombosis. These new insights regarding the drivers of
TAVI-associated thrombosis, coupled with the ongoing development of novel antithrombotics which
do not cause bleeding, hold the potential to deliver newer, safer therapeutic paradigms to prevent
post-TAVI thrombotic and bleeding complications. This review highlights the major challenge of
post-TAVI thrombosis and bleeding, and the significant issues surrounding current antithrombotic
approaches. Moreover, a detailed discussion regarding the mechanisms of post-TAVI thrombosis
is provided, in addition to an appraisal of current antithrombotic guidelines, past and ongoing
clinical trials, and how novel therapeutics offer the hope of optimizing antithrombotic strategies and
ultimately improving patient outcomes.
Keywords: TAVI; aortic valve stenosis; antithrombotic drugs; transcatheter aortic valve implantation;
complications; bleeding; anticoagulation; antiplatelet; mechanisms; therapy
1. Introduction
Severe aortic stenosis (AS) represents a major global healthcare burden, with medical management
being associated with a poor prognosis and high rates of mortality [1]. Calcific aortic stenosis is the
most common type of valvular heart disease requiring intervention, and its prevalence is growing
with the increasing global life expectancy [2]. While prosthetic surgical replacement has traditionally
been the mainstay treatment, the number of patients for which this approach is appropriate has been
limited given that aortic stenosis is predominately a condition of older patients who often have other
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medical co-morbidities [3–5]. The growing demand for non-surgical treatment alternatives for patients
with severe AS, especially in intermediate to high-risk patients, has been one of the driving forces
behind the emergence of transcatheter aortic valve implantation (TAVI) [3].
Since the first procedure in 2002, TAVI has not only offered a new approach to treating calcific
aortic stenosis but has also provided the large cohort of patients deemed intermediate to high surgical
risk access to life-saving treatment [6,7]. This is particularly important since up to one-third of all
patients in need of an aortic valve replacement are unsuitable for surgical aortic valve replacement
(SAVR) [8].
The TAVI procedure involves guiding a prosthetic valve, typically via a transfemoral catheter,
and implanting it into the existing aortic valve [9]. With rapid developments in device design, coupled
with the growing experience of clinicians and the adoption of more efficient techniques, TAVI has
become an increasingly effective procedure with fewer complications.
As a consequence, there have now been more than 500,000 TAVI procedures performed in over
70 countries and at over 1000 centres [10].
2. Basis for Antithrombotic Therapy after Implantation
In spite of these developments, the issue of ischaemic and bleeding events continues to impact the
immediate and long-term morbidity and mortality of patients undergoing TAVI procedures (Table 1).
Table 1. Ischaemic and bleeding complications in post-transcatheter aortic valve implantation (TAVI)
patients [3,11–14].
<30 Days 1 Year 2 Years
Life-threatening/major bleeding
complications (%) 10.2 ± 3.5 15.95 ± 0.9 17.6 ± 0.7
Stroke (%) 4.1 ± 0.7 7 ± 1.7 8.5 ± 2.3
Disabling stroke (%) 2.4 ± 1.3 4.1 ± 1.8 4.9 ± 2.1
New-onset atrial fibrillation (AF) (%) 11.2 ± 1.9 13 ± 4.1 15.4 ± 5.7
Myocardial infarction (%) 0.9 ± 0.1 2.1 ± 0.3 2.7 ± 0.8
All-cause mortality (%) 2.8 ± 0.6 10.3 ± 3.7 15.9 ± 5.6
Cardiovascular mortality (%) 2.6 ± 0.6 7.1 ± 2.9 10.7 ± 4.1
Data presented as the number of events divided by the number of treated patients, using available data from
the Surgical Replacement and Transcatheter Aortic Valve Implantation (SURTAVI) trial, the Placement of Aortic
Transcatheter Valves (PARTNER) 2 cohort and the US CoreValve High Risk study. Results are presented as weighted
mean ± 1 standard deviation. Bleeding complications: major or life-threatening bleeding complications; new-onset
AF: new-onset atrial fibrillation.
Based on the results from the Surgical Replacement and Transcatheter Aortic Valve Implantation
(SURTAVI) trial, the Placement of Aortic Transcatheter Valves (PARTNER) 2 cohort and the US
CoreValve studies [11–13,15], the percentage of stroke events within 30 days of TAVI was 4.1%
(± 0.7), with life-threatening and major bleeding complications observed in 10.2% (± 3.5) of patients.
Within one year, these percentages increased to 7.0% (± 1.7) and 15.95% (± 0.9), respectively.
Importantly, the rate of new-onset atrial fibrillation (AF) was 11.2% (± 1.9) within 30 days,
which confers an increased risk of cerebrovascular events. The all-cause mortality following TAVI was
2.6% (± 0.6) within 30 days, 7.1% (± 2.9) within one year and increased to 10.7% (± 4.1) within two
years of the procedure.
A recent meta-analysis highlighted that post-TAVI bleeding was associated with a 323% increase in
30-day postoperative mortality (odds risk (OR): 4.23, 95% confidence interval (CI): 2.80–6.40; p < 0.0001)
and that patients with major bleeding/life-threatening bleeding showed a 410% increase in mortality
compared with patients without bleeding (OR: 5.10; 95% CI: 3.17–8.19; p < 0.0001). In addition,
the presence of atrial fibrillation was independently correlated with TAVI-associated bleeding (OR: 2.63;
95% CI: 1.33–5.21; p = 0.005) [16].
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In addition to the bleeding risk associated with antithrombotic therapy, it is important to note
that scoring systems, such as the EuroSCORE II and the Society of Thoracic Surgeons (STS) risk score,
can be utilised to stratify the mortality risk of patients undergoing TAVI. These scores incorporate a
range of clinical variables such as age, renal impairment and New York Heart Association Functional
Classification as part of a clinically validated risk assessment model to help predict outcomes in
patients undergoing cardiac procedures [17,18].
However, important factors that heavily influence mortality after percutaneous procedures, such
as frailty and body mass index, are not included in these scoring systems [19]. Highlighting the
important role these clinical variables play in predicting post-procedural mortality in the context of
percutaneous coronary intervention (PCI) and TAVI, frailty is an independent risk factor associated
with one-year mortality post-TAVI (hazard ratio (HR): 3.5, 95% CI: 1.4 to 8.5, p = 0.007) whilst low body
mass index is linked with increased all-cause mortality [20,21].
Therefore, despite the adoption of these prediction scores, the ‘heart team’ plays a central role
in determining suitable candidates for TAVI or SAVR. Thus, with advancements in TAVI systems
and technical knowledge, the focus of heart teams has shifted from discussing the technicalities of
the procedure to assessing the patient and the important prognostic variables not represented by
the EuroSCOREII and STS scoring systems to ensure the selection of patients most likely to benefit
from TAVI.
These results emphasise the importance of appropriate antithrombotic therapy following a TAVI
procedure, given the often high-risk group of patients that undergo TAVI. Moreover, given the high
rates of bleeding observed post-TAVI, these data highlight the clinical need for antithrombotic strategies
that are tailored towards minimizing bleeding risk.
3. Mechanisms of Thrombosis in TAVI
The mechanisms underlying thrombosis associated with TAVI are likely multifactorial. In this
regard, a number of contributing factors potentially explaining the thrombotic risk associated with TAVI
have been proposed. These include: (1) flow disturbances associated with prosthetic valve placement,
(2) the introduction of a prothrombotic metallic frame, and (3) a co-existent prothrombotic tendency
in an older, co-morbid population [22–24]. Emerging evidence suggests that the haemodynamic
disturbances created at sites of valve implantation play a leading role in thrombus formation [22–26].
Indeed, clinical data has demonstrated that the majority of thrombi forming around TAVIs occur on the
aortic side of the implanted valve, between the leaflet and stent. This is significant since deployment
of the stent and bioprostethic valve displaces the native valve, thus creating a so-called neosinus and
smaller native sinus (Figure 1).
Figure 1. The native sinus and neosinus. Deployment of the transcatheter heart valve (THV) results in
the displacement of the native aortic valve leaflets. The displaced native valve leaflets divide the aortic
sinus into two parts—a neosinus (1) and native sinus (2). Flow stagnation in the neosinus appears
to be a key driver of thrombus formation in the context of TAVI. Reproduced with permission from
Yoganathan A, The Fluid Mechanics of Transcatheter Heart Valve Leaflet Thrombosis in the Neosinus;
published by Lippincott Williams & Wilkins, 2017 [27].
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Recent data indicates that flow stagnation in the neosinus is likely to be an important
haemodynamic factor associated with a heightened thrombotic risk [28–34]. These data, coupled
with the clinical observation that prosthesis type and the larger transcatheter heart valves are also
important risk factors for TAVI-associated thrombosis, suggest that patient-specific valve geometries at
the site of implantation are likely a key driver of flow stagnation patterns and thus thrombotic risk [35].
It is well established that flow stagnation results in coagulation reactions that ultimately yield the
generation of thrombin and a fibrin-rich thrombus [15–17].
The placement of the metallic frame creates a further nidus for thrombus formation. Although not
formally tested, it is likely that placement of the metallic frame results in endothelial damage
that in the context of local perturbation of endothelial matrix components and haemodynamic
disturbances creates a prothrombotic milieu. Akin to coronary stents, prior to the endothelialisation
of the metallic frame, the exposed artificial surface acts as a substrate for platelet adhesion and
activation, as well as the initiation of the contact activation coagulation system. Furthermore, it has
recently been established that haemodynamic forces play a central role in mediating platelet
activation [36,37]. Together, these alterations are likely to confound any prothrombotic state.
In this context, there is also a clinically relevant rate of pre- and new-onset AF in TAVI cohorts,
which further exacerbates the risk of thrombosis and stroke, necessitating the use of anticoagulation,
which increases the risk of bleeding complications [38,39]. Despite significant variance in incidence
between registries, a recent meta-analysis revealed that the incidence of AF in the context of TAVI
approximates 10% [40]. Importantly, new-onset AF was associated with an increase in 30-day all-cause
mortality and a significant increase in one-year all-cause death. More recently, a meta-analysis of
65 studies incorporating 43,506 patients found the rate of new-onset AF was the most frequent
arrhythmia post-TAVI [41]. Indeed, 2641 patients developed new-onset AF, with an increasing mean
prevalence of 11%, 14%, 14% and 25% during hospital stay, 30-day, one-year and two-year follow-up
periods, respectively. Significantly, new-onset AF following TAVI increased the risk of death (relative
risk: 1.61, 95% CI: 1.35 to 1.98, I2 = 47%) and cerebrovascular events (1.79, 95% CI: 1.24 to 2.64, I2 = 0%)
accordingly [41].
In addition to the emergence of AF and the local prothrombotic milieu that occurs in the setting
of TAVI, periprocedural stroke can occur as a consequence of the dislodgment of calcified valvular
components upon insertion of the prosthesis [42–44]. Embolic protection devices have been tested in
association with TAVI. Although not analysed yet in large randomised trials, initial data suggest a
reduction of strokes with the use of embolic protection devices [45,46].
4. Leaflet Thrombosis
Recent data has demonstrated that valve leaflet thrombosis is a common occurrence post-TAVI,
with this complication being diagnosed in approximately 10–15% of patients by computed tomography
angiography post-TAVI [47]. Interestingly, data from two registries from observational studies,
SAVORY (Subclinical Aortic Valve Bioprosthesis Thrombosis Assessed with Four-Dimensional
Computed Tomography) and RESOLVE (Assessment of Transcatheter and Surgical Aortic Bioprosthetic
Valve Thrombosis and Its Treatment with Anticoagulation), suggest that leaflet thrombosis is more
strongly prevalent among TAVI cohorts than SAVR cohorts [48], with the cumulative incidence of
symptomatic leaflet thrombosis following TAVI ranging from 0.61% to 2.8% [49,50]. This supports
the notion that, as discussed above, the TAVI procedure is associated with distinct haemodynamic
changes that result in a prothrombotic phenotype. Whilst it is well accepted that subclinical leaflet
thrombosis is a common occurrence, the clinical relevance of valve leaflet thrombosis remains a matter
of much debate. Despite the detection of hypoattenuated leaflet thickening, a surrogate of valve
leaflet thrombosis often being detected incidentally on computed tomography in patients without
symptoms, the formation of valve leaflet thrombosis has been linked to two adverse sequelae, namely
haemodynamic valve deterioration and an increased risk of stroke [51].
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To date, the available evidence suggests that leaflet thrombosis can affect aortic valve pressure
gradients; however, the magnitude of this effect ranges from clinically insignificant leaflet restriction to
symptomatic valve deterioration [50]. In this regard, registry data from a cohort of 1521 TAVI patients
with systematic clinical and echocardiography follow-up demonstrated that the rate of haemodynamic
valve deterioration was 2.8% at one year post-TAVI [52]. Importantly, in all these cases, the underlying
cause of valve deterioration was identified as valve thrombosis. Crucially, the rate of valve leaflet
thrombosis appears to correlate with the antithrombotic regime such that patients managed with oral
anticoagulation have a lower incidence of leaflet thrombosis. Moreover, it has consistently been shown
that the treatment of patients with subclinical leaflet thrombosis with oral anticoagulation leads to a
regression of valve thickening and is correlated with changes in transvalvular pressure gradients [53].
Interestingly, recent data suggest that the development of subclinical leaflet thrombosis following
TAVI is not associated with increased mortality or stroke [54]. This observational study followed
754 patients (120 diagnosed cases of leaflet thrombosis), with no differences observed in all-cause
mortality or the incidence of stroke/transient ischaemic attack (TIA) during a 406-day period (8-month
Kaplan-Meier estimate for mortality: 86.6% vs. 85.4%, p = 0.912; for stroke- or transient ischaemic
attack-free survival 98.5% vs. 96.8%, p = 0.331). In contrast, data from the MAUDE database highlights
that leaflet thrombosis complicated by structural valve disease (SVD) (aortic stenosis or regurgitation)
is associated with adverse outcomes including stroke, cardiogenic shock and death [55]. Indeed, of the
30 patients with leaflet thrombosis and SVD, stroke/TIA occurred in 10%, cardiogenic shock in 6.7%
and death in 30%. These data emphasise that unlike subclinical leaflet thrombosis, clinically manifest
leaflet thrombosis is associated with poor clinical outcomes.
5. Rationale for Optimised Therapy
With the inherent risk of stroke and leaflet thrombosis in the setting of TAVI, post-TAVI
antithrombotic therapy is essential to minimise these risks. However, all currently clinically available
antithrombotic therapy is invariably associated with a risk of bleeding [56]. In the context of TAVI, this
is a particular issue since patients undergoing TAVI often have multiple co-morbidities, such as chronic
kidney disease, that are well known to further increase bleeding risk [35]. Importantly, bleeding
post-TAVI is associated with adverse clinical outcomes and increased mortality, thus diminishing
the benefits of antithrombotic therapy [16]. Therefore, delineating the optimal antithrombotic
therapy and duration of treatment remains an unmet clinical need. To date, the evidence base
guiding antithrombotic therapy post-TAVI is weak, which consequently has yielded guideline
recommendations that are not uniform across professional bodies. In addition to determining
the optimal antithrombotic regime, identifying high-risk patients such as those with concurrent
AF who stand to benefit from more intense antithrombotic regimens and the application of novel
antithrombotics, which are not associated with untoward bleeding risk, remain two outstanding
clinical issues in the context of TAVI.
6. Antithrombotic Therapy Guidelines Post-TAVI
The current guidelines regarding the use of antithrombotic therapy post-TAVI are summarised
in Table 2. As previously discussed, these guidelines are predominantly based on small studies and
consensus opinion. This has led to varying and largely empirical recommendations from different
professional bodies, which is reflected in the heterogeneous antithrombotic regimes used in clinical
practice. Whilst the development of antithrombotic therapies post-TAVI have no doubt been informed
by the experience of SAVR with bioprostheses and PCI, given the very distinct nature of the TAVI
procedure, metallic stent residual calcified valves and the effects of haemodynamics, it is obvious that
more data is required to formulate adequate and uniform TAVI-specific guidelines.
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Table 2. Current antithrombotic guideline recommendations for patients undergoing TAVI.
American College of
Cardiology/American Heart
Association (AHA)/Society of
Thoracic Surgeons [57,58]
European Society of
Cardiology (ESC) [59]
American College of
Chest Physicians [60]
TAVI Post-Procedural
75–100 mg aspirin OD indefinitely Aspirin or clopidogrelindefinitely
50–100 mg aspirin OD
indefinitely (Grade 2C)
75 mg clopidogrel OD for 6 months Aspirin and clopidogrelearly post-TAVI
75 mg clopidogrel OD
for 3 months (Grade 2C)
If VKA indicated, no clopidogrel If VKA indicated,no antiplatelet therapy
Bioprosthetic valves
Low risk
75–100 mg aspirin OD
(Class IIaB a)
Low-dose aspirin
(Class IIaC b)
50–100 mg aspirin OD
indefinitely (Grade 2C)
VKA (target INR 2.5) for at least
3 months
(Class IIbB b)
VKA (target INR 2.0–3.0)
(Class IIbC c)
High risk
75–100 mg aspirin OD
(Class IIaB a)
VKA (target INR 2.5)
(Class IC a)
VKA (target INR 2.0–3.0) (Class I a)
AHA risk factors: new-onset atrial fibrillation (AF), left ventricular dysfunction, previous thrombo-embolism,
and hypercoagulable condition; ESC risk factors: AF, venous thrombo-embolism, hypercoagulable state, or with a
lesser degree of evidence, severely impaired left ventricular dysfunction (ejection fraction≤35%). OD: once daily;
AF: atrial fibrillation; INR: international normalised ratio; TAVI: transcatheter aortic valve implantation;
VKA: vitamin K antagonist. [14]. a Class I: conditions for which there is evidence for and/or general agreement that
the procedure or treatment is beneficial, useful and effective. b Class IIa: weight of evidence/opinion is in favour of
usefulness/efficacy. c Class IIb: usefulness/efficacy is less well established by evidence/opinion.
7. The Role of Dual Antiplatelet Therapy
Current recommendations comprise administering dual antiplatelet therapy (DAPT),
with clopidogrel used for the first 3–6 months and aspirin maintained indefinitely, given there is
no indication for anticoagulation (Table 2). The therapeutic benefit of DAPT following TAVI for
patients in sinus rhythm, however, remains contentious. Indeed, a pooled analysis investigating
672 participants comparing DAPT (aspirin and clopidogrel) vs. single antiplatelet therapy (SAPT)
(aspirin) following TAVI demonstrated no significant discrepancy in the 30-day net adverse clinical and
cerebral event (NACE) rate at one month [61]. The results indicated a NACE rate of 13% and 15% in the
SAPT and DAPT groups respectively (odds ratio (OR): 0.83, 95% confidence interval (CI): 0.48 to 1.43,
p = 0.50). A pattern, however, was noted in favour of fewer life-threatening and major bleeds in the ASA
(aspirin) group compared with DAPT, questioning the value of clopidogrel in this context. Two recent
meta-analyses conducted by Hu et al. and Ahmad et al. reached similar conclusions, suggesting that
DAPT, when compared with SAPT following TAVI, displays non-superiority in reducing thrombotic
events but involves added risk of major and life-threatening bleeds [62,63]. However, these findings
are diluted somewhat by the fact that the analyses are based on small studies, many of which are
non-randomised, with short follow-up periods. This is highlighted by a recent survey of 45 TAVI
centres across Europe, Australasia and the USA, which revealed that 82.2% of the centres surveyed
routinely use DAPT post-TAVI for a median of three months [63].
8. The Role of Anticoagulation Post-TAVI
The role of anticoagulation post-TAVI is vitally important but is still a highly contentious issue.
This has come into focus with the observation that oral anticoagulation (OAC) may prevent subclinical
leaflet thrombosis and valve deterioration [64]. Indeed, the 2017 American Heart Association guidelines
recommend that anticoagulation with VKA to achieve an INR of 2.5 may be reasonable for at least
three months following TAVI in patients at low risk of bleeding [58]. This recommendation is based
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on studies indicating the increased prevalence of subclinical valve thrombosis, as visualised by
multidetector computerised tomographic scanning, in patients administered antiplatelet therapy
alone versus anticoagulation with VKA [65]. However, as discussed above, the clinical relevance
of subclinical leaflet thrombosis (SLT) remains to be established. More significant is the fact that
AF is present in up to one-third of patients undergoing TAVI and, importantly, AF is associated
with increased cardiovascular morbidity and mortality post-TAVI as a result of an elevated risk of
stroke and bleeding related to OAC [38,39]. Indeed, data from the PARTNER trial emphasises this
point, as patients with AF had a doubling of mortality at 12 months (26.2%) compared to those in
sinus rhythm (12.9%) [66]. Strikingly, the mortality of patients with AF who experienced a major
bleeding complication was 48.7%. These data are similar to previous reports in which patients with AF
post-TAVI have been demonstrated to have a marked increase in mortality and significantly higher
rates of bleeding [38,39].
Current guidelines recommend OAC (VKA or novel oral anticoagulant (NOAC)) in addition to
aspirin for patients undergoing TAVI with concurrent AF. This practice has recently been supported
by results from the FRANCE TAVI registry, where anticoagulation was correlated with decreased
risk of bioprosthetic valve dysfunction after TAVI [67]. However, the benefit of combination therapy,
as opposed to OAC alone, has been challenged recently. Indeed, single agent VKA appears as effective
as VKA in combination with antiplatelet therapy, with the rates of stroke, adverse cardiovascular events
and death similar between patients treated for a median of 13 months post-TAVI with VKA alone or
VKA in combination with SAPT or DAPT [68–70]. Again, the use of antiplatelet agents in addition to
VKA conferred a two-fold increase in the risk of major or life-threatening bleeding [68]. The notion
that more intensive antithrombotic regimens may not translate to improved clinical outcomes has
previously been highlighted by the WOEST study, where OAC plus clopidogrel in the setting of PCI
was shown to be associated with significantly lower rates of bleeding and a reduction in all-cause
mortality as compared with triple therapy (OAC in addition to aspirin and clopidogrel) [71].
Recently, the question as to whether NOACs may confer a lower bleeding risk compared to
VKA in the setting of TAVI has begun to be addressed. A consistent finding from the large-scale
trials evaluating NOACs for the prevention of arterial thromboembolism in AF and treatment of
venous thromboembolism (VTE) has been the lower bleeding risk, especially intracranial bleeding,
associated with NOACs in comparison to VKA [69,72]. Recently, a small study demonstrated that
apixaban may allow anticoagulation post-TAVI, albeit with a lower bleeding risk compared to VKA [73].
However, recently, the much-anticipated GALILEO trial was stopped prematurely after interim
analysis demonstrated a rivaroxaban-based antithrombotic regimen, compared to an antiplatelet
regime, was associated with a higher incidence of thromboembolism, all-cause death and bleeding [74].
Whilst a full analysis of the data is awaited, it is important to note that the dose of rivaroxaban used in
this trial was 10 mg, a dose which currently only has evidence for efficacy as a VTE thromboprophylaxis
and for the secondary prevention of VTE. This raises the obvious question as to whether the dose of
rivaroxaban was sufficient in the GALILEO trial. However, the issue of NOACs and their efficacy in
the context of TAVI remains an area of active investigation with a number of ongoing trials (Table 3).
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Table 3. Ongoing trials with novel oral anticoagulants in patients post-TAVI.
POPular-TAVI ATLANTIS ENVISAGE-TAVI AF AUREA AVATAR
(ClinicalTrials. gov)
Identification NCT02247128 NCT02664649 NCT02943785 NCT01642134 NCT02735902
Study Design Multicentre,open-label, randomised
Multicentre, open-label,
randomised, phase IIIb
Multicentre, open-label, randomised,
phase IIIb Multicentre, randomised, phase IV
Multicentre,
open-label, randomised
Patient Cohort No need for long-term OAC
Successful TAVI without
consideration of previous
antithrombotic treatment
Successful TAVI. Patients have AF and
an ongoing indication for OAC.
Patients with successful TAVI
procedure not under
OAC treatment.
Successful TAVI procedure and
patient receiving VKA prior
to procedure
Experimental Drug
Cohort A: 75 mg clopidogrel OD
and <100 mg aspirin OD.
Cohort B: 75 mg clopidogrel
and OAC.
5 mg apixaban. 2.5 mg apixaban,
if the patient has 2 or more factors a
Edoxaban-based regimen 60 mg and
30 mg tablet OD and 15 mg tablet for
transitioning at end of treatment.
Antiplatelet therapy (if prescribed):
aspirin 75–100 mg OD or clopidogrel
75 mg OD
VKA (acenocumarol) VKA (target INR 2–3)
Comparator Cohort A: <100 mg aspirin.Cohort B: OAC.
VKA if AF or antiplatelet therapy if
sinus rhythm
VKA-based regimen oral VKA tablets
as selected and provided by the site.
(Target INR 2–3)
DAPT with 100 mg aspirin and
75 mg clopidogrel
75–100 mg aspirin and VKA (VKA
corresponding to anticoagulation
the patient was receiving prior to
TAVI, monitored and adapted to
current recommendations)
Primary Outcome
Lack of bleeding complications as
per BARC definition 1 year
post-TAVI. Co-primary outcome
defined as freedom of
non-procedure-related bleeding
complications at 1 year post-TAVI.
Composite of death, MI, stroke,
peripheral embolism, intracardiac
or bioprosthesis thrombus, any
episode of DVT or PE, major
bleeding (up to 13 months)
Number of participants experiencing
any of these factors b
(within 36 months). Number of
participants experiencing major
bleeding (within 36 months).
Cerebral thromboembolism by the
detection of cerebral infarction by
MRI within the first 3 months
post-TAVI (within 3 months).
Composite of all-cause death, MI,
stroke, valve thrombosis and
haemorrhage >2 as defined by the
VARC 2. (within 12 months).
Duration
Aspirin for at least 12 months, with
a lifelong recommendation.
Clopidogrel discontinued after
90 days in both cohorts
12 months
VKA continued until efficacy
endpoints are reached or up to
36 months post-randomisation.
Aspirin or clopidogrel discontinued
after 90 days. Patients with stenting
post-TAVI continue aspirin or
clopidogrel up to 12 months, DAPT
allowed for 1 month.
3 months 12 months
Estimated Enrolment 1000 1509 1400 124 170
OAC: oral anticoagulation; DAPT: dual antiplatelet therapy; VARC: valve academic research consortium; BARC: bleeding academic research consortium; INR: international normalised
ratio; MI: Myocardial infarction; PE: pulmonary embolism; DVT: deep vein thrombosis; MRI: Magnetic resonance imaging [75–80]. a age >80years, body weight <60 kg, serum creatinine
>1.5 mg/dL/; b all-cause death, MI, ischaemic stroke, valve thrombosis, and major bleeding.
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9. Ongoing Trials
The POPular-TAVI (antiPlatelet therapy for Patients undergoing Transcatheter Aortic
Valve Implantation) trial is a multicentre open-label randomised trial currently investigating the
hypothesis that monotherapy with aspirin or OAC is safer than dual therapy with clopidogrel
for three months. Cohort A comprises patients on aspirin (up to 100 mg OD) versus aspirin plus
clopidogrel (75 mg OD). Cohort B comprises patients on OAC (according to their indication) versus
OAC plus clopidogrel. The primary outcome evaluated is freedom from non-procedure-related
bleeding at one year and the trial will also assess for net clinical benefit [75].
The ATLANTIS (Anti-Thrombotic Strategy After Trans-Aortic Valve Implantation for
Aortic Stenosis) trial is a Phase IIIb multicentre open-label randomised trial investigating the efficacy
of apixaban following TAVI, compared with DAPT, for 12 months [76]. The experimental arm involves
apixaban 5 mg twice daily, or 2.5 mg for patients over 80 years of age or body weight under 60 kg,
irrespective of them having AF. This is compared with either VKA for patients with AF or standard of
care antiplatelet therapy for sinus rhythm.
The ENVISAGE-TAVI (Edoxaban Versus Standard of Care and Their Effects on Clinical Outcomes
in Patients Having Undergone Transcatheter Aortic Valve Implantation (TAVI) in Atrial Fibrillation)
trial is a multicentre open-label randomised trial comparing edoxaban to VKA-based therapy in
patients with an indication for OAC after TAVI for up to 36 months [77]. The primary outcome
evaluated is net adverse events and major bleeding. Patients are randomised to either 60 mg edoxaban
OD or any VKA. Antiplatelet therapy may also be administered if indicated.
The AUREA (Dual Antiplatelet Therapy Versus Oral Anticoagulation for a Short Time to Prevent
Cerebral Embolism After TAVI) and AVATAR (Anticoagulation Alone Versus Anticoagulation and
Aspirin Following Transcatheter Aortic Valve Interventions) trials are also smaller-scale multicentre
randomised studies comparing VKA with DAPT and aspirin plus VKA therapy respectively for strokes
and other complications [78,79].
10. Insights on Future Research
The ongoing trials discussed will provide important new insights regarding how NOACs may fit
in the antithrombotic paradigm post-TAVI. However, a number of important challenges remain.
The bleeding risk associated with current antithrombotic regimes remains a significant concern.
In this regard, there have been a number of new antithrombotic drugs developed in the last decade
that hold the promise of inhibiting thrombosis without significantly impeding haemostasis [56,81].
Foremost amongst these are inhibitors of protein disulfide isomerase (PDI), a novel PAR4 antagonist,
and inhibitors of the intracellular platelet enzyme PI3K beta [82–84]. Both PDI inhibitors and PAR4
inhibitors are in phase 2/3 clinical trials and if proven safe and effective, could pave the way to a new
range of antithrombotic drugs to be investigated for the prevention of TAVI-associated thrombosis.
Another aspect of TAVI-associated thrombosis that is yet to be tested is whether mechanistically,
the metallic frame associated with the valve causes significant contact factor activation. The RE-ALIGN
trial, which investigated dabigatran for the prevention of thrombosis in patients with mechanical heart
valves, had to be ended prematurely due to the elevated risk of bleeding and thrombosis associated with
dabigatran [85]. Subsequent in vitro data suggest that in the context of mechanical heart valves, contact
factor activation plays a predominant role instigating thrombin generation, which may explain why
warfarin is superior to a direct thrombin inhibitor in this context [86]. Therefore, whether similar effects
in the haemostatic system occur in the context of TAVI requires investigation. Significantly, a novel
anti-XIIa antibody has recently been developed that exhibits marked potency for inhibiting contact
factor activation without any effect on haemostasis and could thus provide scope for another novel,
potentially safer antithrombotic approach post-TAVI [87].
As discussed above, a major outstanding issue is identifying the patients most likely to
benefit from more intense antithrombotic strategies post-TAVI. Our group has developed novel
therapeutic and imaging agents based on a unique single-chain antibody that specifically binds
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to activated platelets [88]. Thus, this technology could be utilised to image patients for the
specific and sensitive detection of valve thrombosis using ultrasound, CT or MRI modalities [88,89].
Intensified antithrombotic therapy could then only be used in patients where thrombus is detected.
Alternatively, this approach would provide the potential to administer platelet-targeted anti-thrombotic
therapy, which we have previously demonstrated to spare haemostasis [90].
In addition to novel therapeutics, there remains much interest within the bioengineering field to
design and develop new valves that may produce fewer haemodynamic disturbances and expose less
thrombogenic material and as such, may result in a lower thrombosis risk [91].
11. Conclusions
The introduction of TAVI represents one of the most successful innovations in cardiovascular
medicine in the last two decades. This has afforded patients with severe aortic stenosis, especially
the elderly and those with significant co-morbidities, access to treatment where surgery is
often contraindicated. With significant improvements in mechanical durability and implantation
technologies, TAVI-related thromboses and bleeding associated with antithrombotic therapy, are
becoming the major determinants of the long-term outcome of TAVI. A growing recognition of the
shortcomings of the current antithrombotic regimes used to prevent TAVI-associated thrombosis
has led to several ongoing clinical trials, which will no doubt inform the development of new
practice guidelines. Simultaneously, with a deepening understanding of the mechanisms causing the
development of post-TAVI thrombosis and the recent advent of a range of novel antithrombotics that
do not inhibit haemostasis, the stage is set for the development of safer and more effective TAVI-specific
antithrombotic therapy.
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